Drug intelligence / Profile preview

THC18

Development stage
Unknown
Lead developer
Althea
Modality
Small Molecules
Administration
Inhalation
01

Overview

THC18 refers to a category of medical cannabis flower products standardized to contain approximately 18% delta-9-tetrahydrocannabinol (THC) by weight. These products are typically derived from specific cannabis strains and are used primarily for inhalation via vaporization. The main active ingredient is delta-9-tetrahydrocannabinol, the principal psychoactive cannabinoid in cannabis, which acts as a partial agonist at cannabinoid receptors CB1 and CB2 in the central nervous system. Medical indications include management of chronic pain, chemotherapy-induced nausea and vomiting, sleep disorders, anxiety-related disorders, and symptoms associated with multiple sclerosis such as spasticity and neuropathic pain[2][4][5]. The effects can include euphoria, relaxation, increased focus or sedation depending on strain composition. Side effects may include dry mouth, drowsiness, dizziness, changes in appetite or mood alterations[2].

Brand names
Althea THC 18RUA Puāwai THC18 White Widow
Other names
Skywalker Kush (strain for Althea THC 18)White Widow (strain for RUA Puāwai THC18 White Widow)
02

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on THC18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on THC18.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call